medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2004, Number 1

<< Back Next >>

Rev Mex Oftalmol 2004; 78 (1)

Estudio comparativo de la eficacia clínica y seguridad de la rimexolona al 1% vs el clorhidrato de olopatadina al 0.1% en pacientes pediátricos con conjuntivitis alérgica moderada a severa

Lombardo-Velásquez II, Juárez EJC, Ordaz FJC

Language: Spanish
References: 7
Page: 22-25
PDF size: 215.43 Kb.


ABSTRACT

Purpose: To compare the efficacy and safety of Rimexolone 1% vs. Olopatadine hydrochloride 0.1% in the management of allergic conjunctivitis.
Materials and methods: In a randomized, double masked, parallel controlled study, 11 patients with allergic conjunctivitis were studied. Those who met inclusion criteria, received masked study medication with instructions to instil drops twice daily (Olopatadine hydrochloride), and three times daily (Rimexolone 1%) in each eye. The patients underwent a complete ophthalmologic examination, and were asked to describe their symptoms, at the beginning, first, second, forth and sixth week.
Results: 9 patients had been treated, 5 girls and 6 boys. Four of them were treated with more than one drug at the same time.
Clinical improvement of the signs and symptoms occurred in six patients with Rimexolone 1%, two with Olopatadine hydrochloride and one with both.
There was an increase of 5 mmHg in the intraocular pressure in one patient. The level returned to the original value after two weeks.
Two patients did not complete the follow up and were excluded from the study.
Conclusion: Both Rimexolone 1% and Olopatadine hydrochloride 0.1% were effective. Rimexolone 1% acted more rapidly and safety with minimal effect on the intraocular pressure.


REFERENCES

  1. Belfort R, Marbeck P. Epidemiological study of 134 subjects with allergic conjunctivitis. Acta Ophthalmol. Scand 2000; 78:38-40.

  2. Aguilar AJ. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. Acta Ophthalmol Scand 2000; 78:52-55.

  3. Nelson LH. Oftalmología Pediátrica. McGraw-Hill- Interamericana, 4a ed. 2000. p.234-237.

  4. Gallin P: Pediatric Ophthalmology, Clinical Guide. Thieme Medical Publishers. 2000. p.98.

  5. Assil K, Massry G y cols. Control of ocular inflammation after cataract extraction with rimexolone 1% ophthalmic suspension. J. Cataract Refract Surg 1997; 23:750-756.

  6. Fan SP y cols. A prospective study on ocular hypertensive and antiinflamatory response to different dosages of fluorometholone in children. Ophthalmology 2001; 108:1973-1977.

  7. Leibowitz H, Bartlett J. Intraocular pressure-raising potencial of 1% rimexolone in patients responding to corticosteroids. Arch Ophthalmol 1996; 114:933-937.




2020     |     www.medigraphic.com